Literature DB >> 21454200

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

Christina Hanzis1, Rohit P Ojha, Zachary Hunter, Robert Manning, Megan Lewicki, Philip Brodsky, Leukothea Ioakimidis, Christina Tripsas, Christopher J Patterson, Patricia Sheehy, Steven P Treon.   

Abstract

We examined the incidence of other malignancies in 924 Waldenström's Macroglobulinemia (WM) patients and their kin. A total of 225 (24.3%) patients had ≥1 additional malignancy, with 63% predating the WM diagnosis. The most common gender-adjusted malignancies were prostate (9.4%), breast (8.0%), non-melanoma skin (7.1%), hematologic (2.8%), melanoma (2.2%), lung (1.4%) and thyroid 1.1%). Among hematologic malignancies, all 13 cases of diffuse large B-cell lymphoma and 4 cases of acute myelogenous leukemia were diagnosed after WM, and were therapy-related. Familial WM subgroup analysis showed a higher incidence of prostate cancer (P=.046) in sporadic WM patients, while patients with familial WM had a higher incidence of lung cancer (P=.0043). An increased incidence of myeloid leukemias (P<.0001) was reported among kin of familial WM patients. These data reveal specific cancer associations with WM, and provide a basis for exploratory studies aimed at delineating a common genetic basis. Additionally, these studies suggest specific cancer clustering based on familial predisposition to WM.

Entities:  

Mesh:

Year:  2011        PMID: 21454200     DOI: 10.3816/CLML.2011.n.016

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  7 in total

1.  Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge.

Authors:  Ahmad T Mansour; Alaleh Esmaeili Shandiz; Michelle K Zimmerman; Trenton D Roth; Jiehao Zhou
Journal:  Am J Blood Res       Date:  2017-04-15

Review 2.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 3.  Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.

Authors:  Prashant Kapoor; Jonas Paludo; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2016-03

4.  Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia.

Authors:  Sabrin Tahri; Tarek H Mouhieddine; Robert Redd; Luisa Lampe; Katarina I Nilsson; Habib El-Khoury; Nang Kham Su; Amin H Nassar; Elio Adib; Govind Bindra; Sarah Abou Alaiwi; Lorenzo Trippa; David P Steensma; Jorge J Castillo; Steven P Treon; Irene M Ghobrial; Adam S Sperling
Journal:  Blood Adv       Date:  2022-04-12

Review 5.  Waldenstrom's Macroglobulinemia: An Update.

Authors:  Maddalena Mazzucchelli; Anna Maria Frustaci; Marina Deodato; Roberto Cairoli; Alessandra Tedeschi
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-01-01       Impact factor: 2.576

6.  A Rare Case of Synchronous Waldenström's Macroglobulinemia and Cutaneous Squamous Cell Carcinoma with a Lung Mass: A Diagnostic and Management Dilemma.

Authors:  Catherine Lynne Limberis; Simon Nayler; Bernardo Leon Rapoport
Journal:  Case Rep Oncol       Date:  2020-12-10

7.  Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study.

Authors:  Nicola Hornung; Mirjam Frank; Nico Dragano; Jan Dürig; Ulrich Dührsen; Susanne Moebus; Raimund Erbel; Andreas Stang; Karl-Heinz Jöckel; Börge Schmidt
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.